Norwood Hospital Among Pioneer Medical Centers in Clinical Trials of Revolutionary Heart Attack Drug TPA-November 14, 1987

FDA Approves Genetically Engineered Clot-Dissolving Protein Tested Locally Under Cardiologist Dr. John Cadigan III

NORWOOD – Marking a monumental milestone in modern cardiology, the federal Food and Drug Administration (FDA) officially approved the use of a revolutionary emergency heart attack drug on Friday, November 13, 1987. Clinically tested on patients at Norwood Hospital and Brockton Hospital, the breakthrough medication—known as TPA (tissue plasminogen activator)—was hailed by local medical leaders as a historic leap forward.

“This therapy is an absolutely revolutionary treatment. It’s the equivalent to curing cancer,” declared Dr. John Cadigan III, a Norwood Hospital cardiologist who served as the coordinator of the clinical trials at the facility. Unlike traditional treatments that merely managed the aftermath of a cardiac event, TPA works by triggering the body’s natural enzymes to dissolve blood clots blocking coronary arteries, halting the progression of a heart attack in its tracks.

Local Trial Success, National Medical Acclaim, and Administration Guidelines

Only three Boston-area community hospitals were chosen to participate in the clinical trials: Norwood Hospital, Brockton Hospital, and Emerson Hospital in Concord. Since trials commenced in November 1986, 35 patients received TPA at Norwood Hospital. According to Dr. Cadigan, a remarkable percentage of the 29 patients who survived their heart attacks showed zero detectable tissue damage to the heart muscle and experienced none of the major bleeding side effects previously associated with clot-dissolving therapies.

Nationally, health leaders praised the milestone:

FDA Commissioner Frank E. Young characterized approval of the genetically engineered protein—developed by South San Francisco-based Genentech Inc.—as a major advance in managing coronary heart disease, noting it could save 10 to 30 percent of first-time heart attack victims depending on how quickly treatment is administered. Comparing a blocked coronary artery to a plugged pipe, Young emphasized, “The faster the plug is dissolved, the faster you restore blood to the heart.”
Dr. Howard Morgan, president of the American Heart Association, stressed that TPA significantly reduces heart muscle damage and mortality if administered within the first few hours after symptom onset.
Dr. James H. Sammons, executive vice president of the American Medical Association, expressed gratification that the drug had successfully transitioned from laboratory research to bedside application.

Medical experts underscored that the treatment’s efficacy depends heavily on prompt action. Dr. Cadigan and federal officials urged individuals experiencing classic heart attack symptoms—such as chest constriction and pain radiating down the left arm—to seek emergency medical care immediately without waiting or denying symptoms. Genentech officials indicated that TPA would arrive in hospital emergency rooms nationwide within two to three weeks, priced in line with international markets at approximately $2,000 per treatment.